
CLAIMS

1. A metal (hydr)oxide composite comprising: a metal (hydr)oxide; and a compound comprising one or more hydroxyl groups in the compound or a salt thereof,

wherein the compound comprising one or more hydroxyl groups in the compound, is one or more compounds selected from the compounds represented by the following Chemical Formula 1 or Chemical Formula 2:

[Chemical Formula 1]




(in Chemical Formula 1,

R1 to R6 are each independently a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group, an ester group, an acyl group, an aromatic ring or a nitro group, and

one or more among R^1 to R^6 are hydroxyl groups),

[Chemical Formula 2]



(in Chemical Formula 2,

A is a nitrogen atom or an oxygen atom,

if A is a nitrogen atom, R^1 may be a hydrogen atom, a halogen atom, a hydroxyl group, or an alkyl group, and if A is an oxygen atom, R^1 does not have a substituent,

R^2 to R^{11} are each independently a hydrogen atom, a halogen atom, a hydroxyl group, a methoxy group, an ester group, an acyl group, or a nitro group, and

one or more of R^1 to R^{11} are hydroxyl groups)

wherein the metal (hydr)oxide is one or more selected from the compounds represented by the following Chemical Formulas 4 and 5:

[Chemical Formula 4]

$[(M^{2+}(OH)_{2-x})((A^{n-})_z)]yH_2O$

(in Chemical Formula 4,

M^{2+} is a divalent metal cation selected from the group consisting of Mg^{2+}, Ni^{2+}, Cu^{2+}, Co^{2+}, and Zn^{2+},

x is a number having a range of 0 or more and 0.4 or less,

A is an anion selected from the group consisting of CO_3^{2-}, NO_3^-, Br^-, Cl^-, SO_4^{2-}, HPO_4^{2-}, and F^-,

n is a charge number of anion A,

n is a number having a range of 0 or more and 2 or less,

z is a number having a range of 0 or more and 1 or less, and

y is a positive number more than 0), and

[Chemical Formula 5]

$[(M^{2+}(O)_{2-x})((A^{n-})_z)]yH_2O$

(in Chemical Formula 5,

M^{2+} is Mg^{2+}, Ni^{2+}, Cu^{2+}, or Zn^{2+},

x is a number of 1 or more and less than 2,

A is an anion selected from the group consisting of CO_3^{2-}, NO_3^-, Br^-, Cl^-, SO_4^{2-}, HPO_4^{2-}, and F^-,

n is a charge number of the anion A,

n is a number having a range of 0 or more and 2 or less,

z is a number having a range of 0 or more and 1 or less, and

y is a positive number more than 0).

2. The metal (hydr)oxide composite of claim 1,

wherein the compound comprising one or more hydroxyl groups in the compound or a salt thereof, has a solubility in water of less than 0.01 mM.

3. The metal (hydr)oxide composite of claim 1 or 2,

wherein the compound comprising one or more hydroxyl groups in the compound or a salt thereof, comprises one or more selected from niclosamide, oxyclozanide, docetaxel, paclitaxel.

4. The metal (hydr)oxide composite of any one of claims 1 to 3,


wherein the metal (hydr)oxide composite is for preventing or treating any one or more diseases among viral infectious diseases, inflammatory diseases and malignant tumor diseases.

5. A pharmaceutical composition comprising: a

metal (hydr)oxide; a compound comprising one or more hydroxyl groups in the compound or a salt thereof; and an additive,

wherein the compound comprising one or more hydroxyl groups in the compound, is one or more compounds selected from the compounds represented by the following Chemical Formula 1 or Chemical Formula 2:

[Chemical Formula 1]




(in Chemical Formula 1,

R^1 to R^6 are each independently a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group, an ester group, an acyl group, an aromatic ring or a nitro group, and

one or more of R^1 to R^6 are hydroxyl groups),

[Chemical Formula 2]



(in Chemical Formula 2,

A is a nitrogen atom or an oxygen atom,

if A is a nitrogen atom, R^1 may be a hydrogen atom, a halogen atom, a hydroxyl group, or an alkyl group, and if A

is an oxygen atom, R^1 does not have a substituent,

R^2 to R^{11} are each independently a hydrogen atom, a halogen atom, a hydroxyl group, a methoxy group, an ester group, an acyl group, or a nitro group), and

wherein the metal (hydr)oxide is one or more selected from the compounds represented by the following Chemical Formulas 4 to 5:

[Chemical Formula 4]

$[(M^{2+}(OH)_{2-x})((A^{n-})_z)]yH_2O$

(in Chemical Formula 4,

M^{2+} is a divalent metal cation selected from the group consisting of Mg^{2+},Ni^{2+}, Cu^{2+}, Co^{2+}, and Zn^{2+},

x is a number having a range of 0 or more and 0.4 or less,

A is an anion selected from the group consisting of CO_3^{2-}, NO_3^-, Br^-, Cl^-, SO_4^{2-}, HPO_4^{2-}, and F^-,

n is a charge number of anion A,

n is a number having a range of 0 or more and 2 or less,

z is a number having a range of 0 or more and 1 or less, and

y is a positive number more than 0), and

[Chemical Formula 5]

$[(M^{2+}(O)_{2-x})((A^{n-})_z)]yH_2O$

(in Chemical Formula 5,

M^{2+} is Mg^{2+},Ni^{2+}, Cu^{2+}, or Zn^{2+},

x is a number of 1 or more and less than 2,

A is an anion selected from the group consisting of CO_3^{2-}, NO_3^-, Br^-, Cl^-, SO_4^{2-}, HPO_4^{2-}, and F^-,

n is a charge number of the anion A,

n is a number having a range of 0 or more and 2 or less,

z is a number having a range of 0 or more and 1 or less, and

y is a positive number more than 0).

6. The pharmaceutical composition of claim 5,

wherein the compound comprising one or more hydroxyl groups in the compound or a salt thereof, comprises one or more selected from niclosamide, oxyclozanide, docetaxel, paclitaxel.

7. The pharmaceutical composition of claim 5 or 6,

wherein 10 to 60 wt% of the metal (hydr)oxide, 0.1 to 60 wt% of the compound or a salt thereof, and 10 to 80 wt% of the additive are comprised based on total 100 wt% of the pharmaceutical composition.

8. The pharmaceutical composition of any one of claims 5 to 7,

wherein the additive is a surfactant.

9. The pharmaceutical composition of any one of claims 5 to 8,

wherein the metal (hydr)oxide and the compound comprising one or more hydroxyl groups in the compound or a salt thereof, are comprised in a rate of 1:0.1 to 10.

10. Use of the pharmaceutical composition of any one of claims 5 to 9 in the manufacture of a medicament for preventing or treating any one or more diseases from viral

infectious diseases, inflammatory diseases and malignant tumor diseases.

11. The pharmaceutical composition of any one of claims 8 to 10,

wherein the surfactant is one or more selected from a polyoxyethylene sorbitan fatty acid ester-based surfactant, a poloxamer-based surfactant, a lecithin-based surfactant, a glycerol fatty acid ester-based surfactant, a sorbitan fatty acid ester-based surfactant, a PEG-based surfactant, a Long chain of sugar, a Gum-based surfactant, a Gelling agent-based surfactant, a thickening polysaccharide-based surfactant and a sodium dodecyl sulfate.

12. Use of the metal (hydr)oxide composite of any one of claims 1 to 4,

for the manufacture of a medicament for preventing or treating any one or more diseases among viral infectious diseases, inflammatory diseases and malignant tumor diseases.

13. The metal (hydr)oxide composite of claim 1,

wherein the metal (hydr)oxide is one or more selected from the compounds represented by Chemical Formula 5, wherein in Chemical Formula 5, M^{2+} is Mg^{2+}, and y is 0.

14. The pharmaceutical composition of claim 5,

wherein the metal (hydr)oxide is one or more selected from the compounds represented by Chemical Formula 5, wherein

in Chemical Formula 5, M^{2+} is Mg^{2+}, and y is 0.

15. The metal (hydr)oxide composite of claim 1,

wherein the metal (hydr)oxide is one or more selected from the compounds represented by Chemical Formula 4, wherein in Chemical Formula 4, M^{2+} is Mg^{2+}, and y is 0.

16. The pharmaceutical composition of claim 5,

wherein the metal (hydr)oxide is one or more selected from the compounds represented by Chemical Formula 4, wherein in Chemical Formula 4, M^{2+} is Mg^{2+}, and y is 0.

17. Use of the metal (hydr)oxide composite of any one of claims 13 to 16,

for the manufacture of a medicament for preventing or treating any one or more diseases among viral infectious diseases, inflammatory diseases and malignant tumor diseases.